StudyFinder

A Randomized Phase III Study of the addition of Venetoclax to Ibrutinib and Obinutuzumab versus Ibrutinib and Obinutuzumab in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL)

Recruiting
I'm interested

This study is NOT accepting healthy volunteers

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

Lauren Aase - lauren.aase@parknicollet.com
Birendra Kumar
Phase III
0123456789
NCT03701282
See this study on ClinicalTrials.gov

Back